Status:
COMPLETED
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Lead Sponsor:
Barnes Retina Institute
Collaborating Sponsors:
Retina Associates of Florida, P.A.
Illinois Retina Associates
Conditions:
Retinal Vein Occlusion
Macular Edema
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF...
Eligibility Criteria
Inclusion
- Ability to provide informed consent
- Visual acuity of 20/40 - 20/320 in the study eye (regardless of relative APD)
- Central foveal thickness (CFT) of \> 250 microns as assessed by OCT (see below)
- Diagnosis of retinal vein occlusion in the past 9 months
- Age over 50 years
Exclusion
- History of previous intraocular surgery in the study eye, including pars plana vitrectomy (but not including uncomplicated cataract surgery), within 60 days of the screening visit
- Inability to make study visits
- Uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg) despite treatment with two or more topical pharmacological anti-glaucomatous medication)
- Pregnancy or lactation
- Evidence of any diabetic retinopathy on exam or history of diabetic macular edema within 12 weeks of study onset
- Any intravitreal injections within 12 weeks of study onset
- Prior retinal vein occlusion
- History of pan-retinal photocoagulation within 3 months of study onset or anticipated within 4 months after study onset
- History of cerebrovascular event or myocardial infarction within 3 months of study onset
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01428388
Start Date
September 1 2011
End Date
December 1 2015
Last Update
October 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Retina Institute
St Louis, Missouri, United States, 63110